| Literature DB >> 15863199 |
Alexandra Böhm1, Maria Piribauer, Friedrich Wimazal, Klaus Geissler, Heinz Gisslinger, Paul Knöbl, Ulrich Jäger, Christa Fonatsch, Paul A Kyrle, Peter Valent, Klaus Lechner, Wolfgang R Sperr.
Abstract
High dose intermittent ARA-C (2x3 g/m(2) i.v., days 1, 3, 5)=HiDAC was introduced as consolidation in AML by the CALGB-group in 1994. We treated 44 de novo AML patients in CR with up to four cycles of HiDAC (four cycles: 56.8%; three cycles: 22.7%; two cycles: 6.8%; one cycle: 13.7%). Median duration of aplasia (ANC<0.5x10(9)/l) was 12 days. Neutropenic fever occurred in 38.6% of the patients during the first, 52.6% during the second, 45.7% during the third, and in 40% during the fourth cycle. Non-hematologic toxicity was tolerable. The median overall- and disease-free survival were 19.3 and 11.3 months, respectively. The best outcome was seen in patients aged <40 years. These results confirm that HiDAC is a safe and effective consolidation in AML.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15863199 DOI： 10.1016/j.leukres.2004.10.009
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156